|  | 


What is Mission Covid Suraksha? All you need to know


On Wednesday, the government launched the ‘COVID Suraksha Mission’, which will assist the development process of approximately five to six Covid-19 vaccine candidates. Starting from the research and development part of the vaccines, the mission will help them obtain the license and finally bring them to market. As several vaccines are in the final phase of trials, this mission will ensure that there are sufficient doses of these vaccines once they are approved.

1. Mission Covid Suraksha involves a grant of Rs 900 crore.

2. The biotechnology department will obtain this grant.

3. The mission aims to provide an end-to-end step for vaccines, from pre-clinical to manufacturing.

4. The Center had announced this package during the third stimulus.

5. The department is supporting the development of 10 vaccines. Five vaccine candidates are in human trials, including the Russian Sputnik-V vaccine.

6. The objective of the project is also to establish clinical trial sites and strengthen existing immunoassay laboratories, central laboratories and adequate facilities for animal studies, production facilities and other testing facilities to support the development of the Covid-19 vaccine, said the DBT.

Prime Minister Narendra Modi recently met with top state ministers via video conference and called on states to be prepared.

“It is not yet decided if there will be one, two or three doses of vaccine. Their prices are not decided either. We have no answers to such questions at this time, as there are different people in the world who do. The business world is involved, there is competition between them, the countries have their diplomatic interests, they also have to wait for the WHO ”, said Modi.

Five vaccines are in different phases of clinical trial in India with the Serum Institute of India conducting the phase 3 trial of the Oxford-Astrazeneca Covid-19 vaccine, while the indigenous Bharat Biotech and ICMR vaccine has already been developed. Phase III clinical trial started. The indigenously developed vaccine by Zydus Cadila has completed the phase 2 clinical trial in the country. Dr Reddy’s Laboratories will soon begin combined phase 2 and 3 clinical trials of the Russian Covid-19 Sputnik V vaccine in India.

Biological E. Ltd has begun the first phase 1 and 2 human trials of its Covid-19 vaccine candidate.

Original source